3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Classical hematology
2
Tumor-Agnostic
1
Conditions
Lymphoproliferative Disorders
2
Anemia, Iron-Deficiency
2
Anemia
2
Interventions
Rituximab
376
Cyclophosphamide
179
Bendamustine Hydrochloride
109
obinutuzumab
100
Vincristine
94
fludarabine
92
ibrutinib
89
Prednisone
89
Doxorubicin
89
venetoclax
86
Lenalidomide
82
Gemcitabine
65
acalabrutinib
48
Brentuximab Vedotin
44
pembrolizumab
43
zanubrutinib
41
Dexamethasone
41
idelalisib
37
ofatumumab
32
Oxaliplatin
30
Chlorambucil
29
polatuzumab vedotin
25
blinatumomab
25
tocilizumab
24
Azacitidine
24
tositumomab I-131
22
Prednisolone
22
tisagenlecleucel
21
glofitamab
21
Nivolumab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
ferric carboxymaltose
×
Lymphoid
×
Clear all
NCT01100879
2022-05-09
AOC-MM
Vifor Pharma
Phase 4
Terminated
3 enrolled
NCT01101399
2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3
Completed
19 enrolled